Overcoming Resistance to FLT3-ITD Therapeutics

FLT3-ITD (internal tandem duplication) is a key driver of acute myeloid leukemia (AML), and several FDA-approved drugs target this mutant kinase. This Viewpoint describes the discovery of inhibitors targeting point mutants and the development of SILA123, a highly potent and selective type II FLT3 inhibitor. In <i>in vivo</i> studies, SILA-123 significantly suppressed tumor growth in allograft models, demonstrating its potential in treating resistant AML.